Results 31 to 40 of about 1,739,286 (305)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

Journal of Immunotherapy for Cancer, 2019
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer.
Z. Guo, B. Lu, Z. Guo, Esther Giehl, M. Feist, Enyong Dai, Weilin Liu, W. Storkus, Yukai He, Zuqiang Liu, D. Bartlett   +10 more
semanticscholar   +1 more source

Target cell-dependent T cell-mediated lysis of vaccinia virus-infected cells [PDF]

, 1975
Vaccinia virus specific cytotoxicity against infected target cells was observed in vitro. Spleen lymphocytes from normal and immunized mice of the inbred strains C3H and DBA/2 were incubated with vaccinia virus-infected and non-infected 51Cr-labeled ...
Alkan, Boyum, Brunner, Calder, Cohen, Epstein, Evans, Fulginiti, Gardner, Gardner, Glasgow, Good, Hecht, Janossy, Julius, Koszinowski, Labowskie, Lohmann-Mathes, Lundstedt, Marker, McFarland, Oldstone, Perlmann, Perlmann, Profitt, Schirrmacher, Shearer, Shortman, Speel, Steele, Ueda, Ueda, Von Pirquet, Wagner, Wagner, Zinkernagel, Zinkernagel   +36 more
core   +1 more source

Vaccinia virus replication is not affected by APOBEC3 family members

Virology Journal, 2006
Background The APOBEC3G protein represents a novel innate defense mechanism against retroviral infection. It facilitates the deamination of the cytosine residues in the single stranded cDNA intermediate during early steps of retroviral infection.
Sutter Gerd, Münk Carsten, Martinez-Fernandez Yolanda, Suezer Yasemin, Kremer Melanie, Schnierle Barbara S   +5 more
doaj   +1 more source

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

Nature Communications, 2017
Both anti-PD1/PD-L1 therapy and oncolytic virotherapy have demonstrated promise, yet have exhibited efficacy in only a small fraction of cancer patients. Here we hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-
Zuqiang Liu, Roshni Ravindranathan, P. Kalinski, Z. Guo, David L. Bartlett   +4 more
semanticscholar   +1 more source

Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma

Molecular Therapy: Oncolytics, 2017
Multiple myeloma is a malignancy of plasma cells of the bone marrow. Although the prognosis is variable, no curative therapy has been defined. Vaccinia virus infects cancer cells and kills such cells in a variety of ways.
Muneyoshi Futami, Kota Sato, Kanji Miyazaki, Kenshi Suzuki, Takafumi Nakamura, Arinobu Tojo   +5 more
doaj   +1 more source

Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins

Journal of Virology, 2018
African swine fever virus (ASFV) causes an acute hemorrhagic fever in domestic pigs, with high socioeconomic impact. No vaccine is available, limiting options for control.
J. Jancovich, David A. G. Chapman, D. Hansen, Mark D. Robida, A. Loskutov, Felicia M. Craciunescu, A. Borovkov, K. Kibler, L. Goatley, K. King, C. Netherton, G. Taylor, B. Jacobs, K. Sykes, L. Dixon   +14 more
semanticscholar   +1 more source

Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. [PDF]

PLoS ONE, 2011
BACKGROUND: Currently existing yellow fever (YF) vaccines are based on the live attenuated yellow fever virus 17D strain (YFV-17D). Although, a good safety profile was historically attributed to the 17D vaccine, serious adverse events have been reported,
Birgit Schäfer, Georg W Holzer, Alexandra Joachimsthaler, Sogue Coulibaly, Michael Schwendinger, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner   +8 more
doaj   +1 more source

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

Frontiers in Immunology, 2023
BackgroundThe attenuated, genetically engineered vaccinia virus has been shown to be a promising oncolytic virus for the treatment of patients with solid tumors, through both direct cytotoxic and immune-activating effects.
Navin K. Chintala, Jennie K. Choe, Erin McGee, Rebecca Bellis, Jasmeen K. Saini, Srijita Banerjee, Andre L. Moreira, Marjorie G. Zauderer, Prasad S. Adusumilli, Prasad S. Adusumilli, Valerie W. Rusch   +10 more
doaj   +1 more source

Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility

Nature Microbiology, 2018
Cell motility is essential for viral dissemination1. Vaccinia virus (VACV), a close relative of smallpox virus, is thought to exploit cell motility as a means to enhance the spread of infection1.
Corina Beerli, A. Yakimovich, S. Kilcher, Glennys V. Reynoso, Gotthold Fläschner, D. Müller, H. Hickman, J. Mercer   +7 more
semanticscholar   +1 more source

Identification of sites phosphorylated by the vaccinia virus B1R kinase in viral protein H5R [PDF]

, 2000
Background: Vaccinia virus gene B1R encodes a erine/threonine protein kinase. In vitro this protein kinase phosphorylates ribosomal proteins Sa and S2 and vaccinia virus protein H5R, proteins that become phosphorylated during infection.
Beaud, G., Brown, N.G., Hardie, G., Leader, D.P., Morrice, D.N.   +4 more
core   +3 more sources